<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541212</url>
  </required_header>
  <id_info>
    <org_study_id>MHICC-2018-003</org_study_id>
    <nct_id>NCT04541212</nct_id>
  </id_info>
  <brief_title>Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia</brief_title>
  <acronym>CarChem</acronym>
  <official_title>Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study of the occurrence of cardiac toxicity in patients with breast&#xD;
      cancer,lymphoma or leukemia receiving chemotherapy including an anthracycline. Patients will&#xD;
      be identified at the oncology clinic and will be included in the study if all eligible&#xD;
      criteria are met. The study will involve retrospective and prospective evaluations.&#xD;
&#xD;
      Safety will be assessed through reporting of serious adverse events (SAEs) related to study&#xD;
      procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to identify and evaluate cardiotoxicity in patients with diagnosis&#xD;
      of breast cancer, lymphoma or leukemia scheduled to receive anthracycline-based chemotherapy&#xD;
      (Cohort A: prospective evaluation); and patients undergoing or having received within the&#xD;
      last 5 years anthracycline-based chemotherapy (Cohort B: retrospective and prospective&#xD;
      evaluations). Part A and B will be conducted in parallel. This study also has the objectif of&#xD;
      identifying biomarkers of cardiotoxicity including inflammatory response proteins and clonal&#xD;
      hematopoiesis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial extracellular volume (ECV)</measure>
    <time_frame>Change from baseline to 3, 6, 12,and 24 months</time_frame>
    <description>Cohort A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial extracellular volume (ECV)</measure>
    <time_frame>Change from baseline to prior study entry, 12 and 24 months post study entry.</time_frame>
    <description>Cohort B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular (LV) systolic function (global and regional)</measure>
    <time_frame>Change from baseline to 3, 6, 12,and 24 months.</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of myocardial injury (high-sensitivity troponin (hs-cTn))</measure>
    <time_frame>Change from baseline to 3, 6, 12,and 24 months.</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of elevated LV fitting pressure (N-Terminal-pro-hormone B-type Natriuretic Peptide (NT-proBNP))</measure>
    <time_frame>Change from baseline to 3, 6, 12,and 24 months.</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of inflammation (high-sensitivity C-reactive protein (hs-CRP))</measure>
    <time_frame>Change from baseline to 3, 6, 12,and 24 months.</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clonal hematopoiesis associated gene mutations.</measure>
    <time_frame>Change from baseline to 24 months..</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telomere length measurement</measure>
    <time_frame>Change from baseline to 24 months..</time_frame>
    <description>Cohort A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular (LV) systolic function (global and regional)</measure>
    <time_frame>Change from study entry to 12 and 24 months.</time_frame>
    <description>Cohort B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of myocardial injury (high-sensitivity troponin (hs-cTn))</measure>
    <time_frame>Change from study entry to 12 and 24 months.</time_frame>
    <description>Cohort B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of elevated LV fitting pressure (N-Terminal-pro-hormone B-type Natriuretic Peptide (NT-proBNP))</measure>
    <time_frame>Change from study entry to 12 and 24 months.</time_frame>
    <description>Cohort B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker of inflammation (high-sensitivity C-reactive protein (hs-CRP))</measure>
    <time_frame>Change from study entry to 12 and 24 months.</time_frame>
    <description>Cohort B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clonal hematopoiesis associated gene mutations.</measure>
    <time_frame>Change from baseline to 24 months..</time_frame>
    <description>Cohort B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Telomere length measurement</measure>
    <time_frame>Change from baseline to 24 months..</time_frame>
    <description>Cohort B</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Prospective</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Retrospective/Prospective</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Imaging</intervention_name>
    <description>Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <other_name>Blood tests</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data Collection</intervention_name>
    <description>Collection of retrospective data</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        300 patients enrolled from oncology clinics. Patients will be screened and identified at&#xD;
        the oncology clinics. The prospective cardiac evaluations including New York Heart&#xD;
        Association (NYHA) functional classification, transthoracic echocardiography, CMR, standard&#xD;
        12-lead electrocardiogram (ECG), cardiac biomarkers, lipid profile &amp; HDL functionality&#xD;
        tests will be performed at the Montreal Heart Institute (MHI).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older at time of CT initiation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients with diagnosis of breast cancer,lymphoma or leukemia (including autografted&#xD;
             subjects)&#xD;
&#xD;
          -  Planned, ongoing or completed (within last 5 years) chemotherapy with anthracycline&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) â‰¥50% pre-chemotherapy&#xD;
&#xD;
          -  The participant is willing to undergo CMR scans and all other required study&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known cardiomyopathy and/or LVEF &lt;50%&#xD;
&#xD;
          -  Known heart failure&#xD;
&#xD;
          -  History of myocardial infarction (MI)&#xD;
&#xD;
          -  Clinically significant cardiac valvular disease&#xD;
&#xD;
          -  Clinically significant pericardial effusion&#xD;
&#xD;
          -  Allografted subjects&#xD;
&#xD;
          -  Contraindications to CMR testing (Cohort A &amp; prospective evaluation for Cohort B):&#xD;
&#xD;
               -  Pacemakers, other metallic implants or severe claustrophobia&#xD;
&#xD;
               -  Weight &gt; 135 kg&#xD;
&#xD;
               -  Patients with a history of previous reaction to any contrast media, allergic&#xD;
                  disorders or bronchial asthma patients with history of seizure&#xD;
&#xD;
               -  Renal insufficiency (eGFR of &lt; 45ml/min/1.73m2 using the MDRD equation)&#xD;
&#xD;
               -  Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Tardif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Claude Tardif, MD</last_name>
    <phone>514-376-3330</phone>
    <phone_ext>3612</phone_ext>
    <email>jean-claude.tardif@icm-mhi.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Cloutier, PhD</last_name>
    <phone>514-461-1300</phone>
    <phone_ext>3581</phone_ext>
    <email>isabelle.cloutier@mhicc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

